

**DRUG NAME: Daunorubicin**

**SYNONYM(S):** daunomycin, DNR, rubidomycin

**COMMON TRADE NAME(S):** CERUBIDINE®

**CLASSIFICATION:** Anthracycline topoisomerase inhibitor

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

**MECHANISM OF ACTION:**

Daunorubicin is an anthracycline antibiotic which damages DNA by intercalating between base pairs resulting in uncoiling of the helix, ultimately inhibiting DNA synthesis and DNA-dependent RNA synthesis. <sup>1</sup> Daunorubicin may also act by inhibiting polymerase activity, affecting regulation of gene expression and generating free radicals. Cytotoxic activity is cell cycle phase non-specific, although it exerts maximal cytotoxic effects in the S-phase.

**PHARMACOKINETICS:**

Interpatient variability	no information found	
Distribution	highest levels in kidney, pancreas and liver; lowest levels in fat, crosses placenta. <sup>2</sup>	
	cross blood brain barrier?	no evidence that it crosses blood brain barrier
	volume of distribution <sup>1,3</sup>	1006-1725 L/m <sup>2</sup>
	plasma protein binding	50-60%
Metabolism	extensively in liver and other tissues	
	active metabolite(s)	daunorubicinol (major metabolite – 60%)
	inactive metabolite(s)	yes
Excretion	urine	14-25%
	feces	hepatobiliary secretion in feces is predominant route of elimination (40%)
	terminal half life	18.5 h
	clearance	236-1117 mL/min/m <sup>2</sup>
Gender	no information found	
Elderly	no information found	
Children	no information found	
Race	no information found	

Adapted from references <sup>1,4</sup> unless specified otherwise.

**USES** <sup>1,4:</sup>

**Primary uses:**

- \*Ewing's sarcoma
- \*Leukemia, acute lymphocytic
- \*Leukemia, acute myeloid
- \*Leukemia, chronic myelogenous
- \*Lymphoma, non-Hodgkin's

\*Health Canada approved indication

**Other uses:**

- Kaposi's sarcoma
- Lymphoma, Hodgkin's disease
- \*Lymphosarcoma
- Rhabdomyosarcoma
- Wilm's tumour

**SPECIAL PRECAUTIONS:**

**Carcinogenicity:** Potentially carcinogenic; mammary tumours and fibrosarcomas have been reported in rat and mice models. <sup>1</sup> Secondary leukemias have been reported in patients receiving topoisomerase II inhibitors in combination with other antineoplastic agents or radiation therapy. In animal studies, peritoneal sarcomas, mammary adenocarcinomas, and fibrosarcomas were observed in test subjects at doses of 1/70<sup>th</sup> to 2 times the recommended human dose based on BSA.<sup>5</sup>

**Mutagenicity:** Mutagenic in Ames test and mammalian *in vitro* tests. <sup>1</sup> Daunorubicin is clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.

**Fertility:** Gonadal suppression resulting in amenorrhea, zoospermia and testicular atrophy in male dogs. <sup>6</sup>

**Pregnancy:** In animal studies with rabbits, an increased incidence of fetal abnormalities (e.g., parieto-occipital cranioschisis, umbilical hernias, or rachischisis) and abortions were observed at doses of 0.05 mg/kg daily (approximately 1/100<sup>th</sup> of the highest recommended human dose based on BSA). In rats, an increased incidence of rib fusions and esophageal, cardiovascular, and urogenital abnormalities were observed at doses of 4 mg/kg daily (approximately half of the recommended human dose based on BSA). Decreased fetal birthweight and post-delivery growth rate were observed in mice.<sup>5</sup>

**Breastfeeding** is not recommended due to the potential secretion into breast milk. <sup>6</sup>

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
allergy/immunology	<b><i>anaphylactoid-type I (rare)</i></b>
	rash
blood/bone marrow febrile neutropenia	<b><i>myelosuppression</i></b> ; nadir 10-14 days, recovery 21-24 days
cardiovascular (arrhythmia)	arrhythmias due to acute cardiac toxicity – uncommon (ECG changes, AV block, bundle branch block)
	transient arrhythmias (6-30%)
	arrhythmias due to late onset cardiac toxicity

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
cardiovascular (general)	<b><i>congestive heart failure</i></b> (rare, dose related)
	<b><i>cardiomyopathy</i></b> (rare, dose related)
	abnormal systolic function on echocardiogram (18-38%) <sup>1</sup>
dermatology/skin	<b><i>extravasation hazard: vesicant</i></b> <sup>7</sup>
	alopecia (very common)
	facial flushing with rapid injection
	flare reaction (histamine release)
	hyperpigmentation
	nail changes
	pain on injection
	radiation recall reaction (rare)
gastrointestinal	<b><i>emetogenic potential: moderate high</i></b> <sup>8</sup>
	diarrhea
	nausea and vomiting (85%)
	<b><i>stomatitis</i></b> <sup>2</sup>
metabolic/laboratory	hyperuricemia (during periods of active cell lysis)
neurology	neuropathy (13%)
renal/genitourinary	red colouration of urine

Adapted from references<sup>1,6</sup> unless specified otherwise.

**Hyperuricemia** may result from cell lysis by daunorubicin and may lead to electrolyte disturbances or acute renal failure.<sup>9</sup> It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with preexisting renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients<sup>10</sup>:

- aggressive hydration: 3 L/m<sup>2</sup>/24 h with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH>7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.<sup>11</sup> It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminum hydroxide (AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminum hydroxide has been added, discontinue sodium bicarbonate.<sup>12</sup>

**Tissue necrosis** may be caused by extravasation of anthracyclines. These agents may bind to DNA and recycle locally to cause a progressive slough of tissue or ulceration over several weeks, requiring excision and skin grafting. For more details on the prevention and management of anthracycline extravasation, refer to BC Cancer [Systemic Therapy Policy III-20: Prevention and Management of Extravasation of Chemotherapy](#).

**Flare reaction** is a painless local reaction along the vein or near the intact injection of anthracyclines. It is characterized by immediate red blotches, streaks and local wheals, probably due to histamine release.<sup>13</sup> Edema may sometimes occur.<sup>13</sup> Patients may or may not experience pruritus or irritation.<sup>13</sup> Symptoms usually subside with or without treatment 30 minutes after the infusion is stopped, although they may last for 1-2 hours and rarely more than

24 hours.<sup>14</sup> For more details on the prevention and management of anthracycline flare reaction, refer to BC Cancer [Systemic Therapy Policy III-20: Prevention and Management of Extravasation of Chemotherapy](#)

**Cardiotoxicity** is thought to be due to free radical damage as myocardial tissue is susceptible to these highly reactive species.<sup>15</sup> Anthracycline cardiotoxicity may present with early or late effects.<sup>16,17</sup> The following information applies to all anthracyclines, anthracenediones and mitoxantrone.<sup>15,17,18</sup>

**Early cardiotoxic effects** are not dose-related and may present from mild ECG changes to life-threatening arrhythmias.<sup>15,16,18</sup> These events may occur during or immediately after a single dose of anthracycline treatment,<sup>15,18</sup> but do not predict subsequent development of delayed cardiotoxicity and are not considered indications for suspension of therapy.<sup>15,16,18-21</sup>

**Late cardiotoxic effects**, which are dose-related and clinically the most important type of cardiotoxic effect, present as reduced LVEF or symptomatic CHF, and typically occur weeks to years after completion of treatment.<sup>15,17-20</sup> Abnormalities in LVEF are associated with all the anthracyclines and their derivatives.<sup>17</sup> LVEF changes are related to the total cumulative dose, are irreversible and refractory to medical therapy.<sup>15,22</sup>

**Prevention and treatment:** Cardiac assessment should occur at baseline and throughout therapy. Monitor for symptomatic congestive heart failure (CHF) or reduced left ventricular ejection fraction (LVEF). Sensitive, non-invasive methods to measure LVEF include radionuclide angiography (RNA), MUGA, or echocardiogram.<sup>17</sup> Late cardiotoxic effects may be prevented by stopping treatment with the associated anthracycline once patients have reached the suggested maximum cumulative dose.<sup>15,22</sup> Management of anthracycline cardiotoxicity includes discontinuation of the drug and initiating standard treatment of CHF.<sup>17</sup>

Cardiotoxicity risk can be reduced but not eliminated with the use of alternative anthracyclines (i.e., epirubicin or liposomal doxorubicin) or by altering the frequency of administration (once a week vs. once every 3 weeks, or continuous infusion).<sup>17</sup> Cardioprotectant therapy with dexrazoxane may be considered for patients with cumulative doxorubicin-equivalent doses greater than 300 mg/m<sup>2</sup>.<sup>18,23,24</sup>

Cumulative doses should be calculated and account for all previous anthracyclines or anthracenediones received during the patient's lifetime. For further information on suggested conversion factors and monitoring thresholds for anthracyclines, see [Dose Conversion for Anthracyclines Exposure](#) in Appendix.

#### INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
ciprofloxacin <sup>25</sup>	may decrease the effect of ciprofloxacin	may decrease ciprofloxacin absorption by altering the intestinal mucosa	monitor patient, increase ciprofloxacin dose if necessary

#### SUPPLY AND STORAGE:

**Injection:** Hikma Canada Limited supplies daunorubicin as a 20 mg ready-to-use, single-use (preservative free) vial in a concentration of 5 mg/mL. Refrigerate. Protect from light.<sup>26</sup>

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

#### SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

**Additional information:**

- Provided as a clear, red solution <sup>1</sup>. Colour change from red to blue-purple indicates decomposition; discard affected solution. <sup>27</sup>
- Contact between daunorubicin and aluminum may result in darkening of the solution and formation of black patches on the aluminum surface after 12-24 hours. <sup>27</sup> Daunorubicin should not be stored in contact with aluminum but it may be injected safely through an aluminum-hubbed needle.

**Compatibility:** consult detailed reference

**PARENTERAL ADMINISTRATION:**

	BC Cancer administration standard noted in <b>bold, italics</b>
Subcutaneous	not used due to corrosive nature <sup>1</sup>
Intramuscular	not used due to corrosive nature <sup>1</sup>
<b>Direct intravenous</b>	over 2-3 min <sup>1</sup> into tubing of running IV; see <a href="#">Systemic Therapy Policy III-20: Prevention and Management of Extravasation of Chemotherapy</a>
<b>Intermittent infusion</b>	<b>over 30-45 min</b> <sup>28-30</sup>
Continuous infusion	dilute in a convenient volume of NS or D5W and infuse through a central venous catheter
Intraperitoneal	not used due to corrosive nature <sup>1</sup>
Intrapleural	not used due to corrosive nature <sup>1</sup>
Intrathecal	not used due to corrosive nature <sup>1</sup>
Intra-arterial	no information available on this route
Intravesical	no information available on this route

**DOSAGE GUIDELINES:**

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or in patients with other toxicities.

**Adults:**

BC Cancer usual dose noted in **bold, italics**

<i>Intravenous:</i>	Cycle Length: 3-4 weeks:	<i>initial therapy:            monotherapy</i> <sup>26</sup> 30-60 mg/m <sup>2</sup> IV once daily for 3-6 consecutive days starting on day 1 (total dose per cycle 90-360 mg/m <sup>2</sup> )  <i>combination therapy</i> <sup>5</sup> 45 mg/m <sup>2</sup> IV once daily for 2-3 consecutive days starting on day 1 (total dose per cycle 90-135 mg/m <sup>2</sup> )  if >60 y old <sup>5</sup> : 30 mg/m <sup>2</sup> IV once daily for 2-3 consecutive days starting on day 1 (total dose per cycle 60-90 mg/m <sup>2</sup> )
---------------------	-----------------------------	--

BC Cancer usual dose noted in ***bold, italics***

Cycle Length:

maximum dose per treatment period: 20 mg/kg<sup>26</sup>

1 week: *maintenance*<sup>26</sup>:  
1 mg/kg IV for one dose on day 1

*Suggested maximum lifetime dose*<sup>26</sup>:

900 mg/m<sup>2</sup>;  
in patients who have received radiation of cardiac region<sup>5</sup>: 400 mg/m<sup>2</sup>

*Dosage in myelosuppression:*

modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"

*Dosage in renal failure:*

reduce dose by 50% if creatinine greater than 265 micromol/L

*Dosage in hepatic failure:*

Bilirubin (micromol/L)	% usual dose
26-51	75%
52-85	50%
> 85	not recommended

*Dosage in dialysis:*

no information found

**Children:**

*Intravenous:*

Cycle Length:

3-4 weeks<sup>6</sup>: >2 y *old* 25-45mg/m<sup>2</sup> IV, frequency of administration dependent on specific regimen employed

<2 y *old* or BSA <0.5 m<sup>2</sup> calculate dose based on BW rather than BSA (mg/kg dose can be approximated by dividing the mg/m<sup>2</sup> dose by 30)

Maximum total cumulative dose<sup>26</sup>:

BW 10 kg: 500 mg/m<sup>2</sup>

BW 20 kg: 600 mg/m<sup>2</sup>

BW 30 kg: 750 mg/m<sup>2</sup>

**REFERENCES:**

1. McEvoy G editor. American Hospital Formulary Systems Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2003.
2. Benjamin R. Clinical Pharmacology of Daunorubicin. Cancer Treat Rep ; 1981;65(4):109-110
3. Robert J, Rigal-Huguet F, Hurlteloup P. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients. Hematological Oncology ; 1992;10(2):111-6
4. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario, Canada: Canadian Pharmacists Association; 2003.
5. AHFS DI® (Adult and Pediatric) (database on the Internet). DAUNOrubicin Citrate, DAUNOrubicin Hydrochloride. UpToDate® Lexidrug®; Accessed February 13, 2025. Updated February 4, 2025. Available at: <http://online.lexi.com>

6. Kastrup E, editor. Daunorubicin, USPDI. Volume 1. Drug Information For the Health Care Professional; Greenwood Village, Colorado: Micromedex, Inc.; 2002.
7. BC Cancer Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer; March 1, 2021.
8. BC Cancer Supportive Care Tumour Group. (SCNAUSEA) BC Cancer Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer; September 1, 2022.
9. DeVita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 2640
10. Leukemia/Bone Marrow Transplant Program of British Columbia. Leukemia/BMT Manual. 4th ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 27
11. Sanofi-Synthelabo. FASTURTEC® product information. Markham, Ontario; 2004.
12. Leukemia/Bone Marrow Transplant Program of British Columbia. Leukemia/BMT Manual. E-Edition ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2010. p. 93–94
13. Mullin S, Beckwith MC, Tyler LS. Prevention and management of antineoplastic extravasation injury. Hospital Pharmacy ; 2000;35:57–74
14. Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. Journal of Clinical Oncology ; 1987;5(7):1116–1126
15. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf ; 2005;4(2):219–234
16. Pfizer Canada Inc. IDAMYCIN® product monograph. Kirkland, Quebec; 19 February, 2009.
17. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol ; September 01, 2007;25(25):3991–4008
18. McEvoy GK, editor. AHFS 2005 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2005.
19. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002.
20. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 1996.
21. Repchinsky C, BSP. Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists association; 2005. p. 676
22. Rose BD editor. Cardiotoxicity in patients receiving chemotherapy. Waltham, Massachusetts: UpToDate®; accessed 22 September, 2005.
23. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol ; June 15, 2002;20(12):2895–2903
24. Hensley M, Hagerty K, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol ; 2009;27(1):127–145
25. Johnson EJ, MacGowan AP, Potter MN, et al. Department of Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol, UK. Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother ; May, 1990;25(5):837–42
26. Hikma Canada Limited. Daunorubicin Hydrochloride injection product monograph. Mississauga, Ontario; June 28, 2023.
27. Trissel L editor. Handbook on Injectable Drugs. Ninth Edition ed. Bethesda, MD: American Society of Health System Pharmacists; 1996.
28. AHFS Drug Information® (database on the Internet). Daunorubicin Citrate, Daunorubicin Hydrochloride. Lexi-Comp Inc.; Accessed 20 August, 2014. Available at: <http://online.lexi.com>
29. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 434–436
30. BC Cancer Agency Leukemia/BMT Tumour Group. (ULKATOP) BCCA Protocol Summary for First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and Daunorubicin. Vancouver, British Columbia: BC Cancer Agency; 1 July, 2014.